Short Interest in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Declines By 38.7%

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTPGet Free Report) was the recipient of a large drop in short interest in February. As of February 28th, there was short interest totalling 14,600 shares, a drop of 38.7% from the February 13th total of 23,800 shares. Currently, 1.2% of the shares of the stock are short sold. Based on an average trading volume of 473,200 shares, the days-to-cover ratio is presently 0.0 days.

60 Degrees Pharmaceuticals Trading Up 8.0 %

Shares of NASDAQ SXTP opened at $1.89 on Monday. The firm has a market capitalization of $2.78 million, a PE ratio of -0.19 and a beta of 4.52. 60 Degrees Pharmaceuticals has a 1 year low of $1.41 and a 1 year high of $35.99. The firm’s 50-day moving average is $3.26 and its 200-day moving average is $4.95.

Analyst Ratings Changes

Several brokerages have recently issued reports on SXTP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Friday, March 7th. HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research note on Tuesday, February 25th.

Get Our Latest Stock Analysis on SXTP

60 Degrees Pharmaceuticals Company Profile

(Get Free Report)

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.

Featured Articles

Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.